Overview
Nasopharyngeal carcinoma (NPC) is a cancer that arises in the nasopharynx, the upper part of the throat behind the nose. It is relatively uncommon worldwide but more frequent in certain regions of East and Southeast Asia, including southern China. Because early NPC can cause few or no symptoms, diagnosis is often delayed until the disease is more advanced. That makes accurate screening and diagnostic tests especially important in outpatient clinics, where many patients present with vague complaints such as nasal congestion, ear fullness, or neck lumps.
This multicenter cohort study evaluated the diagnostic value of a newer Epstein-Barr virus (EBV)-related marker, anti-EBV BNLF2b total antibody, also called P85-Ab, in patients with suspected NPC. The study compared P85-Ab with several commonly used EBV serologic markers: viral capsid antigen immunoglobulin A (VCA-IgA), early antigen IgA (EA-IgA), and nuclear antigen 1 IgA (EBNA1-IgA). The main question was simple but clinically important: which test performs best in real outpatient practice when NPC is suspected?
The findings suggest that P85-Ab is a strong and reliable biomarker for suspected NPC, with particularly high sensitivity and specificity. In some patient groups, especially those with no symptoms or only nonspecific symptoms, P85-Ab alone may be sufficient. In patients with symptoms more suggestive of NPC, combining P85-Ab with other EBV antibodies may improve detection.
Why EBV biomarkers matter in NPC
EBV is strongly linked to NPC, especially the non-keratinizing type commonly seen in endemic areas. When a person develops NPC, the immune system may produce antibodies against EBV proteins. These antibodies can be detected in blood and used as clues to the presence of cancer.
Traditional EBV markers, such as VCA-IgA and EBNA1-IgA, have been used for years, but their performance is not perfect. Some patients with NPC test negative, while some people without cancer test positive, leading to missed diagnoses or unnecessary referrals. A better biomarker would ideally detect most true NPC cases while minimizing false alarms.
P85-Ab targets BNLF2b, an EBV protein. Because this marker is newer, clinicians have needed clearer evidence about how well it works in a typical outpatient setting, rather than only in research centers or selected high-risk groups.
Study design and participants
This was a prospective, multicenter cohort study conducted from April 2021 to March 2024 across outpatient clinics in five medical centers in China. The study included people with clinically suspected NPC, meaning physicians had enough concern based on symptoms, examination, or imaging to warrant EBV testing and follow-up.
A total of 3,795 eligible participants were recruited consecutively. After excluding those with poor-quality samples or loss to follow-up, 3,777 participants remained in the final analysis. Of these, 1,680 were ultimately diagnosed with NPC and 2,097 did not have NPC. The median age was 49 years, and about 65% were men.
The follow-up period was long enough to support diagnostic confirmation, with a median follow-up of 27.2 months. That is important because NPC diagnosis may require endoscopic examination, imaging, pathology, and observation over time to ensure accuracy.
How the biomarkers were tested
P85-Ab was measured using a chemiluminescent immunoassay, a highly sensitive laboratory technique that detects antibody-antigen binding through light emission. The comparison markers were measured by enzyme-linked immunosorbent assays, or ELISAs, which are widely used in clinical laboratories.
The study focused mainly on two diagnostic properties:
1. Sensitivity: the ability of the test to correctly identify people who truly have NPC.
2. Specificity: the ability of the test to correctly identify people who do not have NPC.
In cancer diagnosis, both are important. High sensitivity helps avoid missed cases, while high specificity helps prevent unnecessary anxiety, imaging, biopsies, and referrals.
Main findings
P85-Ab performed better than the other EBV biomarkers overall. Its sensitivity was 93.0% and its specificity was 97.3%. These are strong diagnostic results, especially for an outpatient test used in real-world clinical practice.
By comparison, the other markers showed lower sensitivity, ranging from 60.4% to 93.0%, and specificity below 90%. In practical terms, this means P85-Ab was better at both finding true NPC cases and ruling out people without the disease.
The test also remained highly sensitive in important subgroups. Among asymptomatic participants, sensitivity was 92.0%. Among patients with symptoms that were not specific for NPC, such as nonspecific nasal or throat complaints, sensitivity was 88.4%. These are clinically meaningful results because early NPC often hides in exactly these groups, where symptoms are subtle or ambiguous.
For participants with NPC-specific symptoms, the study evaluated a triplet strategy combining P85-Ab, VCA-IgA, and EBNA1-IgA. In that subgroup, the combined approach improved sensitivity compared with P85-Ab alone: 95.9% versus 93.1%. This difference was statistically significant. However, in asymptomatic patients and those with nonspecific symptoms, adding the other antibodies did not provide additional diagnostic benefit beyond P85-Ab alone.
What the results mean in clinical practice
These findings suggest a practical, risk-stratified approach to EBV testing in suspected NPC.
For patients who have no symptoms but are being evaluated because of concern raised by screening, family history, or incidental findings, P85-Ab alone may be enough as an initial biomarker. The same may apply to patients with nonspecific symptoms that could be caused by many benign conditions.
For patients with symptoms more characteristic of NPC, such as persistent nasal obstruction, blood-stained nasal discharge, unilateral middle ear effusion, neck mass, or cranial nerve-related symptoms, adding VCA-IgA and EBNA1-IgA to P85-Ab may slightly improve sensitivity and help catch more cases.
This tailored approach is attractive because it balances diagnostic accuracy with simplicity and efficiency. Fewer unnecessary tests may reduce cost and streamline outpatient workflows, while still preserving the ability to detect cancer early.
Why this study is important
NPC can be difficult to diagnose early because its symptoms overlap with common benign ear, nose, and throat conditions. In endemic regions, clinicians often rely on a combination of symptoms, endoscopy, imaging, pathology, and EBV serology to decide who needs further workup.
This study is important because it evaluates a newer biomarker in a realistic clinical setting, not just in a narrowly selected group. The large sample size, multicenter design, and prospective follow-up strengthen the reliability of the findings. Most importantly, it directly compares P85-Ab with established markers, helping clinicians understand where the new test fits into practice.
If confirmed in additional populations and healthcare systems, P85-Ab could become a valuable first-line blood test for suspected NPC, especially where early detection is a public health priority.
Limitations and cautions
As with all diagnostic studies, the results should be interpreted carefully. First, the study population came from medical centers in China, where NPC is more common than in many other parts of the world. The performance of P85-Ab may differ in populations with different genetic backgrounds, EBV exposure patterns, or disease prevalence.
Second, diagnostic markers are only one part of the workup. A positive blood test does not confirm cancer by itself, and a negative test does not completely rule it out if clinical suspicion remains high. Endoscopy, imaging, and biopsy remain essential for definitive diagnosis.
Third, while the triplet strategy improved sensitivity in patients with NPC-specific symptoms, this came with a more complex testing approach. In everyday practice, clinicians must balance the benefits of higher sensitivity against cost, laboratory access, and turnaround time.
Finally, as with any biomarker study, external validation in other regions and care settings will be important before broad adoption.
Take-home message
Anti-EBV BNLF2b total antibody, or P85-Ab, showed excellent diagnostic performance for suspected NPC in outpatient settings. It outperformed traditional EBV antibody markers overall and maintained strong accuracy in patients with no symptoms or nonspecific symptoms. For patients with symptoms more suggestive of NPC, combining P85-Ab with VCA-IgA and EBNA1-IgA may further improve detection.
In short, P85-Ab appears to be a promising biomarker that could help clinicians detect nasopharyngeal carcinoma earlier and more accurately, especially in regions where the disease is most common.
